Head-to-head evidence
Alogliptin vs Vildagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Alogliptin · Nesina
Marketed by Takeda Pharmaceutical Company
NCT00286429 · Phase 3 · completed
The 390-participant trial was randomized, quadruple-blind, and placebo-controlled, with 130, 131, and 129 participants assigned to placebo, alogliptin 12.5 mg, and alogliptin 25 mg, respectively. Both primary HbA1c comparisons were statistically significant in favor of alogliptin, but HbA1c is a surrogate measure, so the evidence does not establish a strong clinical-outcome grade.
Next expected readout: December 2026 · NCT07093476 (registry estimate)
Vildagliptin · Galvus
Developed by Novartis
NCT00099866 · Phase 3 · completed
The study was randomized and double-blind, with an active metformin comparator and 570 participants. Its primary endpoint was the surrogate measure of HbA1c change, and because no trial results are posted, it cannot be determined whether the primary comparison was favorable.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alogliptin's landscape · Vildagliptin's landscape